
Opinion|Videos|August 23, 2024
Subcutaneous Amivantimab: Overcoming Treatment Barriers and Shaping Advanced NSCLC Strategies
Author(s)Martin Dietrich, MD, PhD, Wade Iams, MD
Focusing on treatment practices for patients with advanced EGFR-mutant NSCLC, Martin Dietrich, MD, PhD, discusses how the availability of subcutaneous amivantamab can potentially address current treatment barriers.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How may the availability of subcutaneous amivantamab:
- Address current treatment barriers/challenges and expand treatment options for patients with advanced NSCLC?
- Impact 1L and 2L treatment strategies and the future role of amivantamab?
Advertisement
Related to this article

Data from the phase 1/2 ALKOVE-1 trial support the FDA approval of neladalkib in this non–small cell lung cancer population.

Alembic’s binimetinib 15-mg and 45-mg tablets, given with encorafenib, received final FDA approval for BRAF-mutant melanoma and NSCLC.

An NDA submission had been completed for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion–mutant NSCLC based on REZILIENT3 data.

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.

An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.

The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs vs T-Cell-Redirecting Therapies at First Relapse in Relapsed/Refractory Multiple Myeloma
2
Why CAR T May Belong Before Bispecifics in Multiple Myeloma
3
How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?
4
Applying CELMoD Class-Level and Agent-Level Evidence to Treatment Selection in Relapsed/Refractory Multiple Myeloma
5

